Oracle Corporation (NYSE:ORCL) is one of the Best Technology Stocks to Buy for the Long Term. On March 6, Reuters reported that Oracle Corporation (NYSE:ORCL) and OpenAI have abandoned plans to expand a flagship AI data center in Texas due to prolonged negotiations over financing and OpenAI’s evolving needs. The report highlighted that the project was part of the Stargate initiative, which is a $5...
Oracle Corporation (NYSE:ORCL) is one of the Best Technology Stocks to Buy for the Long Term. On March 6, Reuters reported that Oracle Corporation (NYSE:ORCL) and OpenAI have abandoned plans to expand a flagship AI data center in Texas due to prolonged negotiations over financing and OpenAI’s evolving needs. The report highlighted that the project was part of the Stargate initiative, which is a $500 billion, 10-gigawatt endeavor. The initiative involved SoftBank Group, OpenAI, and Oracle, and was announced by President Donald Trump in January 2025. In September, both the companies had announced plans of 600-megawatt expansion near the Abilene, Texas flagship site. According to sources familiar with the matter, the capacity is now expected to shift to another data center campus under construction. The sources also noted that the Abilene site features eight buildings operated by Oracle Cloud Infrastructure, with two already operational. Moreover, the plans for an additional 4.5 gigawatts remain on track. According to Reuters, the fallout between Oracle and OpenAI has created opportunities for Meta Platforms to lease the Abilene expansion site from developer Crusoe, facilitated by Nvidia. Oracle Corporation (NYSE:ORCL) is an American multinational computer technology company specializing in database software, cloud infrastructure, and enterprise software solutions. The company offers one of the industry’s broadest and deepest suites of AI-powered cloud applications. While we acknowledge the potential of ORCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Follow Insider Mon...
Oracle Corporation (NYSE:ORCL) is one of the Best Technology Stocks to Buy for the Long Term. On March 6, Reuters reported that Oracle Corporation (NYSE:ORCL) and OpenAI have abandoned plans to expand a flagship AI data center in Texas due to prolonged negotiations over financing and OpenAI’s evolving needs. The report highlighted that the project was part of the Stargate initiative, which is a $5...
Oracle Corporation (NYSE:ORCL) is one of the Best Technology Stocks to Buy for the Long Term. On March 6, Reuters reported that Oracle Corporation (NYSE:ORCL) and OpenAI have abandoned plans to expand a flagship AI data center in Texas due to prolonged negotiations over financing and OpenAI’s evolving needs. The report highlighted that the project was part of the Stargate initiative, which is a $500 billion, 10-gigawatt endeavor. The initiative involved SoftBank Group, OpenAI, and Oracle, and was announced by President Donald Trump in January 2025. In September, both the companies had announced plans of 600-megawatt expansion near the Abilene, Texas flagship site. According to sources familiar with the matter, the capacity is now expected to shift to another data center campus under construction. The sources also noted that the Abilene site features eight buildings operated by Oracle Cloud Infrastructure, with two already operational. Moreover, the plans for an additional 4.5 gigawatts remain on track. According to Reuters, the fallout between Oracle and OpenAI has created opportunities for Meta Platforms to lease the Abilene expansion site from developer Crusoe, facilitated by Nvidia. Oracle Corporation (NYSE:ORCL) is an American multinational computer technology company specializing in database software, cloud infrastructure, and enterprise software solutions. The company offers one of the industry’s broadest and deepest suites of AI-powered cloud applications. While we acknowledge the potential of ORCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Follow Insider Mon...
Oracle Corporation (NYSE:ORCL) is one of the Best Technology Stocks to Buy for the Long Term. On March 6, Reuters reported that Oracle Corporation (NYSE:ORCL) and OpenAI have abandoned plans to expand a flagship AI data center in Texas due to prolonged negotiations over financing and OpenAI’s evolving needs. The report highlighted that the project was part of the Stargate initiative, which is a $5...
Oracle Corporation (NYSE:ORCL) is one of the Best Technology Stocks to Buy for the Long Term. On March 6, Reuters reported that Oracle Corporation (NYSE:ORCL) and OpenAI have abandoned plans to expand a flagship AI data center in Texas due to prolonged negotiations over financing and OpenAI’s evolving needs. The report highlighted that the project was part of the Stargate initiative, which is a $500 billion, 10-gigawatt endeavor. The initiative involved SoftBank Group, OpenAI, and Oracle, and was announced by President Donald Trump in January 2025. In September, both the companies had announced plans of 600-megawatt expansion near the Abilene, Texas flagship site. According to sources familiar with the matter, the capacity is now expected to shift to another data center campus under construction. The sources also noted that the Abilene site features eight buildings operated by Oracle Cloud Infrastructure, with two already operational. Moreover, the plans for an additional 4.5 gigawatts remain on track. According to Reuters, the fallout between Oracle and OpenAI has created opportunities for Meta Platforms to lease the Abilene expansion site from developer Crusoe, facilitated by Nvidia. Oracle Corporation (NYSE:ORCL) is an American multinational computer technology company specializing in database software, cloud infrastructure, and enterprise software solutions. The company offers one of the industry’s broadest and deepest suites of AI-powered cloud applications. While we acknowledge the potential of ORCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Follow Insider Mon...
The Dow Jones Industrial Average and other major stock indexes were mixed in late-morning trade Wednesday after a key inflation report held no surprises. Meanwhile, crude prices jumped after the International Energy Agency agreed to release a substantial amount of oil.
The Dow Jones Industrial Average and other major stock indexes were mixed in late-morning trade Wednesday after a key inflation report held no surprises. Meanwhile, crude prices jumped after the International Energy Agency agreed to release a substantial amount of oil.
Palantir Technologies Inc. (NASDAQ:PLTR) is one of the Best Technology Stocks to Buy for the Long Term. According to a CNBC report released on March 6, Palantir Technologies Inc. (NASDAQ:PLTR) was an outlier in a tough week for the stock market amidst US attack on Iran. The stock rallied 15%, while the NASDAQ declined 1.2%. The report noted that as President Donald Trump has not signaled any speed...
Palantir Technologies Inc. (NASDAQ:PLTR) is one of the Best Technology Stocks to Buy for the Long Term. According to a CNBC report released on March 6, Palantir Technologies Inc. (NASDAQ:PLTR) was an outlier in a tough week for the stock market amidst US attack on Iran. The stock rallied 15%, while the NASDAQ declined 1.2%. The report noted that as President Donald Trump has not signaled any speedy resolution to the ongoing conflicts, investors have gravitated towards Palantir Technologies Inc. (NASDAQ:PLTR) which drives around 60% of its revenue from government contracts. According to CNBC, Rosenblatt maintained a Buy rating on the stock and raised the price target to $200 from $150, noting the Middle East conflict enhances the company’s government pipeline. The firm highlighted “adequate alternatives” to Anthropic’s Claude models and potential for more deals like last year’s $10 billion contract with the US Army. Palantir Technologies Inc. (NASDAQ:PLTR) is a software company that develops and deploys data integration and analytics platforms for government agencies, defense organizations, and enterprise clients. Its notable products include Palantir Gotham, Foundry, and Apollo. While we acknowledge the potential of PLTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Follow Insider Monkey on Google News.
On Tuesday, word spread that the National Institutes of Health was launching a series of what it's calling "Scientific Freedom Lectures," with the first scheduled for March 20 . The "freedom" theme echoes one of the major concerns of the director of the NIH, Jay Bhattacharya, who feels he suffered outrageous censorship of his ideas during the pandemic and is using his anger about it to fuel his ef...
On Tuesday, word spread that the National Institutes of Health was launching a series of what it's calling "Scientific Freedom Lectures," with the first scheduled for March 20 . The "freedom" theme echoes one of the major concerns of the director of the NIH, Jay Bhattacharya, who feels he suffered outrageous censorship of his ideas during the pandemic and is using his anger about it to fuel his efforts to bring change to the NIH. Given that scientific freedom is a major interest of the director, you might think that the first lecture would be delivered by a distinguished scientist. Guess again. The speaker at the first lecture will be a former journalist best known for his fringe ideas on COVID and the climate. The topic will be the possibility that SARS-CoV-2 was accidentally released from a lab, an idea for which there is no scientific evidence. Freedom for me Bhattacharya was one of the signatories of the Great Barrington Declaration, which argued that we should try to protect the elderly and vulnerable but otherwise enable COVID to spread through the rest of the population. By and large, public health officials were aghast at the likely consequences—overwhelmed hospital systems, a still-substantial rate of mortality among healthy adults, the consequences of more cases of long COVID, etc.—and argued strongly against it. Read full article Comments
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the Best Technology Stocks to Buy for the Long Term. On March 9, Advanced Micro Devices, Inc. (NASDAQ:AMD) announced entering into a multi-year licensing agreement with Adeia. Through this deal AMD gains access to Adeia’s IP portfolio covering hybrid bonding, packaging, and processing technologies. This comes as both the companies settled their d...
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the Best Technology Stocks to Buy for the Long Term. On March 9, Advanced Micro Devices, Inc. (NASDAQ:AMD) announced entering into a multi-year licensing agreement with Adeia. Through this deal AMD gains access to Adeia’s IP portfolio covering hybrid bonding, packaging, and processing technologies. This comes as both the companies settled their dispute over semiconductor technology, as reported by Reuters on March 9. Adeia had filed two patent lawsuits against Advanced Micro Devices in Texas federal court. Paul E. Davis, Adeia’s CEO, noted: “We are pleased to reach this agreement with AMD, a global leader in high-performance computing and advanced semiconductor solutions,” Adeia has pioneered fundamental advances in the semiconductor industry over the last 30 years and maintains a large and growing IP portfolio licensed to leading firms worldwide. This settlement removes legal overhang for Advanced Micro Devices, Inc. (NASDAQ:AMD). That said, on March 5, Stacy Rasgon from Bernstein assigned a Hold rating on the stock with a price target of $235. The analyst noted that Washington is drafting a resolution that will require companies including Advanced Micro Devices to get a license to export AI chips. While the regulation is yet to be finalized it can add extra friction for chipmakers. Advanced Micro Devices, Inc. (NASDAQ:AMD) is a global semiconductor company focused on high-performance computing, graphics, and visualization technologies. Its main products include microprocessors, graphics processors, personal computers, workstations, and embedded system applications. While we acknowledge the potential of AMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ...
Fifth Third CEO Tim Spence says AI isn’t hype. In fact, it’s already writing 40% of his bank’s code and helping double the company’s size with fewer employees. He’s seeing meaningful, long-term productivity gains and a faster path to growth. And he says the next phase is even bigger: AI that doesn’t just support customers, but actually executes financial tasks on their behalf. Tim Spence joined Bl...
Fifth Third CEO Tim Spence says AI isn’t hype. In fact, it’s already writing 40% of his bank’s code and helping double the company’s size with fewer employees. He’s seeing meaningful, long-term productivity gains and a faster path to growth. And he says the next phase is even bigger: AI that doesn’t just support customers, but actually executes financial tasks on their behalf. Tim Spence joined Bloomberg Open Interest to talk about the AI revolution in banking. (Source: Bloomberg)
Earnings Call Insights: OppFi Inc. (OPFI) Q4 2025 Management View CEO Todd Schwartz opened the call by highlighting "another year of record-breaking performance at OppFi." He stated total revenue increased 13.5% year-over-year and adjusted net income rose 69% year-over-year, with a Net Promoter Score of 78. Schwartz detailed the rollout and benefits of underwriting Model 6, which "is designed to i...
Earnings Call Insights: OppFi Inc. (OPFI) Q4 2025 Management View CEO Todd Schwartz opened the call by highlighting "another year of record-breaking performance at OppFi." He stated total revenue increased 13.5% year-over-year and adjusted net income rose 69% year-over-year, with a Net Promoter Score of 78. Schwartz detailed the rollout and benefits of underwriting Model 6, which "is designed to identify riskier borrowers and properly price risk across segments," noting adjustments to persist growth through higher summer delinquencies. The auto approval rate in Q4 was 79%, aiding an 8% year-over-year increase in originations for the quarter. Schwartz announced plans to release Model 6.1 in the first half of 2026 and Model 7.0 in Q3 2026, both expected to improve originations and reduce risk. Schwartz described the ongoing development of LOLA, OppFi's next-generation origination and servicing system. "We plan to substantially migrate to our new software system in Q3 2026," he said, expecting LOLA to enhance funnel metrics, increase automated approvals, improve efficiency, and integrate systems. He also announced a new line of credit product launching with bank partners in summer 2026, intended to serve new geographies and expand credit access. CFO Pamela Johnson emphasized the company's strong quarter: "generating revenues of $159 million, an impressive 17% increase over Q4 '24." Johnson attributed growth to Model 6, which improved risk-based pricing and underwriting. She reported originations increased 8% to $230 million and ending receivables rose 16% to $493 million. Johnson explained that "net charge-offs as a percentage of revenue increased to 45% for the quarter, up from 42% in the prior year quarter," while total expenses before interest declined to 28% of revenue from 33% last year. She added, "adjusted net income increased 27% to a fourth quarter record of $26 million, an increase from $20 million last year, and adjusted earnings per share grew 28% to $0.30 ...
Shares of Mineralys Therapeutics MLYS were up 4.4% yesterday after the company announced that the FDA has accepted the new drug application (NDA) for its product candidate, lorundrostat, to treat adult patients with hypertension in combination with other antihypertensive drugs. A final decision from the regulatory body in the United States is expected on Dec. 22, 2026. Per management, if approved,...
Shares of Mineralys Therapeutics MLYS were up 4.4% yesterday after the company announced that the FDA has accepted the new drug application (NDA) for its product candidate, lorundrostat, to treat adult patients with hypertension in combination with other antihypertensive drugs. A final decision from the regulatory body in the United States is expected on Dec. 22, 2026. Per management, if approved, lorundrostat has the potential to provide a new treatment option for patients with resistant and uncontrolled hypertension. The above NDA was based on positive data from a successful clinical program, which demonstrated favorable safety and blood pressure reduction in adults with hypertension. MLYS’ Price Performance Shares of Mineralys have plunged 21.6% so far this year against the industry’s rise of 6.1%. Image Source: Zacks Investment Research MLYS’ Explore-OSA Data on Lorundrostat Concurrent with the FDA accepting the NDA for lorundrostat, the company also reported top-line data from the phase II Explore-OSA exploratory study, which evaluated lorundrostat for treating overweight or obese adults with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. Data from the Explore-OSA study showed that four weeks of treatment with lorundrostat (50 mg), dosed in the evening, failed to demonstrate a clinically meaningful difference in the apnea-hypopnea index (AHI) versus placebo, the study’s primary endpoint. However, treatment with lorundrostat did demonstrate a clinically meaningful reduction in blood pressure and favorable safety and tolerability in patients with difficult-to-control hypertension. Lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor, is being studied for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as chronic kidney disease (CKD) and OSA. Last year, Mineralys announced that the pivotal phase III Launch-HTN study and the phase II Advance-HTN study of lorundrostat in...
The IEA is considering releasing oil barrels from reserves with brent over $90, though mixed messages from US officials were met with market volatility. (Source: Bloomberg)
The IEA is considering releasing oil barrels from reserves with brent over $90, though mixed messages from US officials were met with market volatility. (Source: Bloomberg)
Former Starbucks (SBUX) CEO Howard Schultz announced on LinkedIn that he and his wife Sheri have moved from Seattle to Miami, marking the end of a more than four-decade chapter in Washington State. The announcement came just hours after Washington lawmakers approved a controversial new “millionaires tax,” fueling speculation that the timing may not be coincidental. In a reflective post Tuesday, Sc...
Former Starbucks (SBUX) CEO Howard Schultz announced on LinkedIn that he and his wife Sheri have moved from Seattle to Miami, marking the end of a more than four-decade chapter in Washington State. The announcement came just hours after Washington lawmakers approved a controversial new “millionaires tax,” fueling speculation that the timing may not be coincidental. In a reflective post Tuesday, Schultz described the move as the next step in retirement after building Starbucks from a small Seattle coffee retailer into one of the most recognizable global brands. “Last year we traveled to dozens of places around the world—places we were too busy to see when building Starbucks and raising kids,” Schultz wrote. “And we have moved to Miami for our next adventure together.” While Schultz framed the relocation as a lifestyle decision (citing South Florida’s sunshine and proximity to their children on the East Coast) the timing has drawn attention in business and political circles. Move Comes Same Day as Washington Passes Millionaires Tax Schultz’s relocation announcement arrived the same day Washington lawmakers approved a new tax targeting ultra-high-net-worth residents. The policy, commonly referred to as a “millionaires tax,” would impose additional taxes on individuals with substantial wealth, particularly through higher levies on large financial holdings. Supporters say the measure will generate billions in revenue for education, childcare, and social programs. Critics argue it risks driving entrepreneurs, executives, and investors out of the state. The debate has intensified concerns about so-called “tax flight,” where wealthy residents relocate to lower-tax jurisdictions. Florida, where Schultz says he has relocated, is one of the most common destinations because it has no state income tax and some of the most tax-friendly policies in the U.S. While Schultz did not reference the legislation directly, his post included a pointed reflection on Washington’s economic cli...
hapabapa AI robotics startup Mind Robotics has raised $500M in a funding round led by Accel and Andreessen Horowitz. The new round values the company at $2B, sources told The Wall Street Journal. Mind Robotics was formed in 2025 as an industrial AI and robotics spinoff from Rivian Automotive ( RIVN ) to apply physical AI and robotics to manufacturing and other industrial operations. Rivian Automot...
hapabapa AI robotics startup Mind Robotics has raised $500M in a funding round led by Accel and Andreessen Horowitz. The new round values the company at $2B, sources told The Wall Street Journal. Mind Robotics was formed in 2025 as an industrial AI and robotics spinoff from Rivian Automotive ( RIVN ) to apply physical AI and robotics to manufacturing and other industrial operations. Rivian Automotive ( RIVN ) still holds an undisclosed stake in the California-based company. The goal for Mind Robotics' AI-powered robots is that they can perform physical work in Rivian ( RIVN ) automotive plants and other factories. The expectation is that the robots will help with manufacturing by picking up parts, assembling components, and manipulating items such as wiring harnesses. Rivian ( RIVN ) has assisted Mind Robotics by training the AI in the robots by using data from thousands of cameras inside its factories. "Our focus is to deploy robots doing real work -- doing real jobs," noted Mind Robotics Chairman RJ Scaringe, who is also Rivian's ( RIVN ) CEO. Shares of Rivian Automotive ( RIVN ) were down 0.8% in Wednesday morning trading. The EV stock is down more than 16% on a year-to-date basis. More on Rivian Rivian: R2 Launch And Technology Advances Create A Long-Term Opportunity Rivian Automotive, Inc. (RIVN) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Rivian Automotive, Inc. (RIVN) Presents at J.P. Morgan 2026 Global Leveraged Finance Conference Transcript Rivian gains new bull at TD Cowen on upbeat R2 outlook Rivian hopes to make a splash at SXSW with the R2 launch
Intel Corporation (NASDAQ:INTC) is one of the Best Technology Stocks to Buy for the Long Term. Intel Corporation (NASDAQ:INTC) has gained more than 9% since the release of its Core Series 2 processor with P-cores on March 9. The company launched its new processor series at Embedded World 2026, targeting mission-critical industrial edge applications that require deterministic performance and real-t...
Intel Corporation (NASDAQ:INTC) is one of the Best Technology Stocks to Buy for the Long Term. Intel Corporation (NASDAQ:INTC) has gained more than 9% since the release of its Core Series 2 processor with P-cores on March 9. The company launched its new processor series at Embedded World 2026, targeting mission-critical industrial edge applications that require deterministic performance and real-time reliability. Management noted that the new processor addresses industrial workloads from safety-critical controls to data processing. Moreover, the company highlighted that the Core Series is a significant improvement compared to its competitor, AMD Ryzen 7 9700X. The processor delivers 4.4 times lower PCIe latency, 2.5 times more deterministic response time, 3.8 times better deterministic performance, and 1.5 times higher multi-thread performance compared to Ryzen 7 9700X. During the same event, Intel also launched the Edge AI suite for Health & Life Sciences. The suite features validated pipelines for AI-powered patient monitoring, including ECG arrhythmia detection, remote photoplethysmography, and 3D visual tracking. Photo by Slejven Djurakovic on Unsplash Management noted that a preview version of the Edge AI suite for Health & Life Sciences is available on GitHub, while the general availability is planned in Q2 2026. Intel Corporation (NASDAQ:INTC) was founded in 1968 and is headquartered in Santa Clara, California, in the heart of Silicon Valley. The company designs and manufactures computer processors and other semiconductor hardware used in personal computers, servers, and a wide range of connected devices. While we acknowledge the potential of INTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT:...
Intel Corporation (NASDAQ:INTC) is one of the Best Technology Stocks to Buy for the Long Term. Intel Corporation (NASDAQ:INTC) has gained more than 9% since the release of its Core Series 2 processor with P-cores on March 9. The company launched its new processor series at Embedded World 2026, targeting mission-critical industrial edge applications that require deterministic performance and real-t...
Intel Corporation (NASDAQ:INTC) is one of the Best Technology Stocks to Buy for the Long Term. Intel Corporation (NASDAQ:INTC) has gained more than 9% since the release of its Core Series 2 processor with P-cores on March 9. The company launched its new processor series at Embedded World 2026, targeting mission-critical industrial edge applications that require deterministic performance and real-time reliability. Management noted that the new processor addresses industrial workloads from safety-critical controls to data processing. Moreover, the company highlighted that the Core Series is a significant improvement compared to its competitor, AMD Ryzen 7 9700X. The processor delivers 4.4 times lower PCIe latency, 2.5 times more deterministic response time, 3.8 times better deterministic performance, and 1.5 times higher multi-thread performance compared to Ryzen 7 9700X. During the same event, Intel also launched the Edge AI suite for Health & Life Sciences. The suite features validated pipelines for AI-powered patient monitoring, including ECG arrhythmia detection, remote photoplethysmography, and 3D visual tracking. Photo by Slejven Djurakovic on Unsplash Management noted that a preview version of the Edge AI suite for Health & Life Sciences is available on GitHub, while the general availability is planned in Q2 2026. Intel Corporation (NASDAQ:INTC) was founded in 1968 and is headquartered in Santa Clara, California, in the heart of Silicon Valley. The company designs and manufactures computer processors and other semiconductor hardware used in personal computers, servers, and a wide range of connected devices. While we acknowledge the potential of INTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT:...
Intel Corporation (NASDAQ:INTC) is one of the Best Technology Stocks to Buy for the Long Term. Intel Corporation (NASDAQ:INTC) has gained more than 9% since the release of its Core Series 2 processor with P-cores on March 9. The company launched its new processor series at Embedded World 2026, targeting mission-critical industrial edge applications that require deterministic performance and real-t...
Intel Corporation (NASDAQ:INTC) is one of the Best Technology Stocks to Buy for the Long Term. Intel Corporation (NASDAQ:INTC) has gained more than 9% since the release of its Core Series 2 processor with P-cores on March 9. The company launched its new processor series at Embedded World 2026, targeting mission-critical industrial edge applications that require deterministic performance and real-time reliability. Management noted that the new processor addresses industrial workloads from safety-critical controls to data processing. Moreover, the company highlighted that the Core Series is a significant improvement compared to its competitor, AMD Ryzen 7 9700X. The processor delivers 4.4 times lower PCIe latency, 2.5 times more deterministic response time, 3.8 times better deterministic performance, and 1.5 times higher multi-thread performance compared to Ryzen 7 9700X. During the same event, Intel also launched the Edge AI suite for Health & Life Sciences. The suite features validated pipelines for AI-powered patient monitoring, including ECG arrhythmia detection, remote photoplethysmography, and 3D visual tracking. Photo by Slejven Djurakovic on Unsplash Management noted that a preview version of the Edge AI suite for Health & Life Sciences is available on GitHub, while the general availability is planned in Q2 2026. Intel Corporation (NASDAQ:INTC) was founded in 1968 and is headquartered in Santa Clara, California, in the heart of Silicon Valley. The company designs and manufactures computer processors and other semiconductor hardware used in personal computers, servers, and a wide range of connected devices. While we acknowledge the potential of INTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT:...
There have been few better stocks to own since 2023 than Palantir (PLTR 0.19%). The stock is up by more than 2,200% since then, although it's now down by more than 25% from the all-time high it touched in October. But it has rallied in recent weeks from the 40% it was down. With that rally in focus, investors may be wondering: Is Palantir primed to soar again, or is it just following the broader m...
There have been few better stocks to own since 2023 than Palantir (PLTR 0.19%). The stock is up by more than 2,200% since then, although it's now down by more than 25% from the all-time high it touched in October. But it has rallied in recent weeks from the 40% it was down. With that rally in focus, investors may be wondering: Is Palantir primed to soar again, or is it just following the broader market's movements? Palantir has put up incredible growth figures Palantir's software platform uses artificial intelligence (AI) to process large volumes of data quickly and give people with decision-making authority the best guidance possible in real time. Originally, this platform was used for government purposes only, such as supporting intelligence gathering and military operations. While this is still a large use case for Palantir's products, the company has also expanded into the commercial sector, where it has achieved significant adoption, particularly in the U.S. Palantir is delivering impressive growth -- its revenue rose 70% year over year during its fiscal fourth quarter to $1.4 billion. Commercial revenue grew at an 82% pace versus government revenue growth of 60%, but both numbers are so impressive that it's hard to find fault in either of them. The best segment was (unsurprisingly) U.S. commercial, which rose 137% to $507 million. What's even more impressive is Palantir's total customer count. Palantir has 571 U.S. commercial clients, which is relatively small compared to the number of potential customers out there. Expand NASDAQ : PLTR Palantir Technologies Today's Change ( -0.19 %) $ -0.29 Current Price $ 150.85 Key Data Points Market Cap $361B Day's Range $ 150.68 - $ 153.17 52wk Range $ 66.12 - $ 207.52 Volume 13M Avg Vol 49M Gross Margin 82.37 % It's hard to find a fault in any of Palantir's results; they are truly impressive. The biggest issue most investors have with the stock is its valuation. Trading at a jaw-dropping 116 times forward earnings, Palan...
Key Points Palantir's growth rate continues to accelerate. The stock is trading at an incredibly high premium. 10 stocks we like better than Palantir Technologies › There have been few better stocks to own since 2023 than Palantir (NASDAQ: PLTR). The stock is up by more than 2,200% since then, although it's now down by more than 25% from the all-time high it touched in October. But it has rallied ...
Key Points Palantir's growth rate continues to accelerate. The stock is trading at an incredibly high premium. 10 stocks we like better than Palantir Technologies › There have been few better stocks to own since 2023 than Palantir (NASDAQ: PLTR). The stock is up by more than 2,200% since then, although it's now down by more than 25% from the all-time high it touched in October. But it has rallied in recent weeks from the 40% it was down. With that rally in focus, investors may be wondering: Is Palantir primed to soar again, or is it just following the broader market's movements? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Palantir has put up incredible growth figures Palantir's software platform uses artificial intelligence (AI) to process large volumes of data quickly and give people with decision-making authority the best guidance possible in real time. Originally, this platform was used for government purposes only, such as supporting intelligence gathering and military operations. While this is still a large use case for Palantir's products, the company has also expanded into the commercial sector, where it has achieved significant adoption, particularly in the U.S. Palantir is delivering impressive growth -- its revenue rose 70% year over year during its fiscal fourth quarter to $1.4 billion. Commercial revenue grew at an 82% pace versus government revenue growth of 60%, but both numbers are so impressive that it's hard to find fault in either of them. The best segment was (unsurprisingly) U.S. commercial, which rose 137% to $507 million. What's even more impressive is Palantir's total customer count. Palantir has 571 U.S. commercial clients, which is relatively small compared to the number of potential customers out there. It's hard to find a fault in any of Palantir's results; they are ...
Shares of Denali Therapeutics, Inc. DNLI have gained 11.8% in the past month against the industry’s decline of 0.5%. The stock has also outperformed the sector and the S&P 500 Index. Investors’ optimism about the potential approval of lead candidate tividenofusp alfa for Hunter syndrome next month is driving the stock. The target action date is April 5, 2026. DNLI Outperforms Industry, Sector & S&...
Shares of Denali Therapeutics, Inc. DNLI have gained 11.8% in the past month against the industry’s decline of 0.5%. The stock has also outperformed the sector and the S&P 500 Index. Investors’ optimism about the potential approval of lead candidate tividenofusp alfa for Hunter syndrome next month is driving the stock. The target action date is April 5, 2026. DNLI Outperforms Industry, Sector & S&P 500 Index Image Source: Zacks Investment Research Let us delve into DNLI’s fundamentals, growth prospects, challenges and valuation levels to make a prudent choice in this scenario. DNLI Pins Hopes on Hunter Syndrome Drug Denali’s DNL310, or tividenofusp alfa, is an Enzyme Transport Vehicle (ETV)-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome). It is designed to cross the blood-brain barrier and deliver the IDS enzyme throughout the body and brain. DNL310 represents one of Denali’s most important near-term value drivers. The company’s biologics license application seeking accelerated approval in the United States is currently under FDA review, with a target action date of April 5, 2026. If approved, the therapy could significantly strengthen Denali’s growth outlook, as Hunter syndrome is a rare disorder with limited effective treatment options, particularly for central nervous system symptoms. The regulatory timeline was previously extended from January 5, 2026 to April 5, 2026 after the FDA classified Denali’s submission of updated clinical pharmacology data as a major amendment to the application. Importantly, the agency did not request additional clinical data, suggesting the delay was procedural rather than related to efficacy or safety concerns. Regulatory momentum for tividenofusp alfa remains strong. The therapy has received Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, highlighting both the unmet medical need and the potential for expedited development pathwa...
Holders of Ardagh Group SA ’s credit default swaps are set for a payout worth 66% of face value following a debt restructuring that saw unsecured bondholders take over the Irish packaging firm. Notes issued by Ardagh Packaging Finance Plc were valued at 33.9 cents on the euro in an auction to settle the insurance-like contracts tied to them, according to a notice on the Creditfixings website . CDS...
Holders of Ardagh Group SA ’s credit default swaps are set for a payout worth 66% of face value following a debt restructuring that saw unsecured bondholders take over the Irish packaging firm. Notes issued by Ardagh Packaging Finance Plc were valued at 33.9 cents on the euro in an auction to settle the insurance-like contracts tied to them, according to a notice on the Creditfixings website . CDS holders will receive a payout equal to the difference between the auction price for the notes and their face value. The auction concludes months of fierce debate over when the swaps were triggered, and therefore how they should be settled. External expert adjudicators appointed by the Credit Derivatives Determinations Committee (CDDC) – a panel which oversees the CDS market – ruled in December that the “credit event” happened by Oct. 7, before the restructuring went live. That could set a precedent for buyers of credit protection at a time when a growing number of restructuring deals are taking place out of court. Read More: CDS Payout Uncertainty Is Pushing Investors Out of Ardagh Trade The payout also draws a line under another contentious issue – whether the unsecured bonds, which were swapped into equity in November, could be delivered in the auction. Arini Capital Management , a major Ardagh creditor and CDS seller, argued against inclusion . It said the bonds had no outstanding principal balance when the CDS were triggered and were bound to be exchanged for equity even if the restructuring had not been completed at that point. Buyers of Ardagh’s CDS, including Tresidor Investment Management and Laurion Capital Management , pushed back, saying that the terms had not been amended at the time the CDS were triggered and therefore the notes should be included as a deliverable obligation. The CDDC eventually dismissed Arini’s challenge.
Jim Ratcliffe’s Ineos Grenadiers cycling team will be renamed and rebranded with a new lead sponsor and new kit before the start of this year’s Tour de France in Barcelona on 4 July. The Guardian understands that while Ratcliffe and Ineos head of sport, Dave Brailsford, will retain ownership and management of the team, the new title sponsor of the World Tour cycling team will be Danish IT supplier...
Jim Ratcliffe’s Ineos Grenadiers cycling team will be renamed and rebranded with a new lead sponsor and new kit before the start of this year’s Tour de France in Barcelona on 4 July. The Guardian understands that while Ratcliffe and Ineos head of sport, Dave Brailsford, will retain ownership and management of the team, the new title sponsor of the World Tour cycling team will be Danish IT supplier Netcompany. It is believed that the Copenhagen-based company will, over five years, invest around €100m (£86m) in the team, which is enjoying renewed success this spring, under the stewardship of Brailsford and the recently retired Tour de France winner, Geraint Thomas. However, Ineos and fellow sponsor Total Energies will also continue to support the team. The additional investment will mean Ineos relinquishing naming rights, but will allow Ratcliffe’s team to compete more effectively at the highest level in Europe’s Grand Tours. The billionaire has long coveted further success in the Tour de France and the injection of the £86m , spread over five years, would elevate his World Tour cycling team closer to the annual £51m budget levels of four-time Tour winner, Tadej Pogacar and his dominant UAE Emirates team. The British team has struggled to compete with the all-conquering Pogacar, partly due to a diminished budget and the inability to secure the peloton’s top talent. “We have had a rough couple of years, but we’re on the way back,” Thomas, currently with the team at Paris-Nice, said this week. “There’s still a long way to go, but we’ve got a great team of riders, of staff, and everyone’s motivated, pushing forward.” A spate of recent multimillion euro buyouts of the peloton’s top talents, including Scotland’s Oscar Onley, now with Ineos Grenadiers, double Olympic champion Remco Evenepoel, and the highly rated Spaniard, Juan Ayuso, have also increased the pressures on budgets as sponsors seek riders capable of competing with Pogacar. View image in fullscreen Tadej Pogaca...
FilippoBacci Rising geopolitical tensions in the Middle East are beginning to ripple through financial markets, prompting traders to reassess the outlook for the global economy. Activity on prediction market Kalshi suggests investors are increasingly factoring in the possibility of a U.S. recession in 2026 as uncertainty surrounding the region intensifies. According to current market pricing on th...
FilippoBacci Rising geopolitical tensions in the Middle East are beginning to ripple through financial markets, prompting traders to reassess the outlook for the global economy. Activity on prediction market Kalshi suggests investors are increasingly factoring in the possibility of a U.S. recession in 2026 as uncertainty surrounding the region intensifies. According to current market pricing on the prediction platform, traders estimate a 27.9% probability that the U.S. economy will enter a recession before the end of the year. While that figure has eased slightly from the 30.4% probability recorded on March 10, it still represents a notable increase from earlier in the year. On February 1, Kalshi participants had assigned only a 20.8% chance of a recession occurring in 2026, highlighting how sentiment has shifted recently. Equity markets have also shown signs of strain. The Dow Jones Industrial Average ( DJI ) is down 1.6% year-to-date and has fallen 6.3% from its recent peak of 50,512.79, which was reached on February 10. The S&P 500 ( SP500 ) has similarly declined 1.6% in 2026, standing 3.3% below its year-to-date high of 7,002.28, recorded on January 28. Meanwhile, the technology-heavy Nasdaq Composite ( COMP:IND ) has experienced steeper losses. The index is down 3.3% so far this year and sits 5.4% below its January 28 high of 23,988.27, reflecting broader caution among investors as geopolitical risks and economic uncertainty continue to build. Dow Focused Funds: ( DIA ), ( DDM ), ( UDOW ), ( DOG ), ( DXD ), and ( SDOW ). S&P 500 Focused Funds: ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( FXAIX ), ( VFIAX ), ( VFFSX ), and ( SWPPX ). Nasdaq Focused Funds: ( QQQ ), ( QQQM ), ( SQQQ ), ( TQQQ ), ( QLD ), and ( QID ). More on markets Treasury yields edge higher after CPI data meets forecast estimates When will U.S. strikes on Iran end? Prediction markets say a nearly 50% chance by month's end Despite oil's 10% slide, predicti...